Who is a candidate for eculizumab treatment for NMOSD?

The SOLIRIS Infusion Finder provides access to a locator tool, which shows sites providing infusion services. This article contains billing and coding guidelines that complement the Local Coverage Determination (LCD) Drugs and Biologicals, Coverage of, for Label and ... Jan 23, 2024 ... This trial was a phase 3, patient-blinded, randomized control study assessing the impact of eculizumab on the course of acute renal failure in patients with ... Mar 7, 2025 ... Soliris, whose active substance is eculizumab, is a first‐in‐class biologic therapy designed to inhibit a key protein in the complement cascade— ... Oct 24, 2017 ... The US Food and Drug Administration (FDA) approved eculizumab as a treatment for adult patients with generalized myasthenia gravis (gMG) who are anti- ... Your browsing activity is empty. Activity recording is turned off. Turn recording back on. See more... Follow NCBI. Connect with NLM. National Library of ... eculizumab ... A drug used to prevent red blood cells from being destroyed in patients with a rare red blood cell disorder called paroxysmal nocturnal ... Alexion Pharmaceuticals, Inc. SOLIRIS. Prescribing information. Alexion Pharmaceuticals, Inc. Pittock SJ, Berthele A, Fujihara K, et al. Eculizumab in aquaporin ... A specific anti-complement treatment (eculizumab; its brand name is Soliris) ... If eculizumab is started, how long does it need to be continued? When a ... Drug-induced liver injury (DILI), a rare, but potentially life-threatening drug reaction with elevated liver enzymes that may lead to liver failure or a need ...